Journal of Neuro-Oncology

, Volume 67, Issue 1–2, pp 65–73 | Cite as

Neurotoxicity of Platinum Compounds: Comparison of the Effects of Cisplatin and Oxaliplatin on the Human Neuroblastoma Cell Line SH-SY5Y

  • Elisabetta Donzelli
  • Maria Carfì
  • Mariarosaria Miloso
  • Alberto Strada
  • Stefania Galbiati
  • Martine Bayssas
  • Genevieve Griffon-Etienne
  • Guido Cavaletti
  • Maria Grazia Petruccioli
  • Giovanni Tredici


The main dose-limiting side effect of cancer treatment with platinum compounds is peripheral neurotoxicity. To investigate the intracellular mechanisms of platinum drugs neurotoxicity we have studied the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. Both platinum compounds are toxic causing cellular death by inducing apoptosis but oxaliplatin is less neurotoxic than cisplatin. The study of the proteins involved in the intracellular transduction pathways that may cause apoptotic death, revealed a very similar pattern of changes after exposure to cisplatin or oxaliplatin. In particular, as demonstrated by densitometric analysis, after exposure to both platinum compounds the total amount of the anti-apoptotic protein Bcl-2 was significantly reduced. Conversely, the amount of the pro-apoptotic protein p53 significantly increased. Caspases 3 and 7 were activated, but their activation was a late event, indicating a secondary role in the apoptotic process. Among the mitogen activated protein kinases, only the p38 protein was activated (phosphorylated) early enough to have a possible role in inducing apoptosis, possibly through p53 stabilization. The results of the present study and the data of the literature demonstrate that the ways in which cisplatin and oxaliplatin are neurotoxic are very similar and include not only DNA damage, but also the modulation of specific molecules involved in regulating the cellular equilibrium between apoptotic death and the cell cycle.

apoptosis Bcl-2 caspase cisplatin MAPK oxaliplatin p53 SH-SY5Y cells 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9–17, 2002CrossRefPubMedGoogle Scholar
  2. 2.
    Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60: 895–924, 2000CrossRefPubMedGoogle Scholar
  3. 3.
    Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053–1071, 1998CrossRefPubMedGoogle Scholar
  4. 4.
    Screnci D, McKeage MJ: Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77: 105–110, 1999CrossRefPubMedGoogle Scholar
  5. 5.
    Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D: Morphometric study of sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 84: 364–371, 1992CrossRefPubMedGoogle Scholar
  6. 6.
    Tredici G, Tredici S, Fabbrica D, Minoia C, Cavaletti G: Experimental cisplatin neuronopathy and the effect of retinoic acid administration. J Neuro-Oncol 36: 31–40, 1998CrossRefGoogle Scholar
  7. 7.
    Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G: Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9: 443–447, 1998CrossRefPubMedGoogle Scholar
  8. 8.
    Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG: Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46: 342–351, 1998CrossRefPubMedGoogle Scholar
  9. 9.
    Cavaletti G, Tredici G, Petruccioli MG, Dondé E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Griffon-Etienne G: Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37: 2457–2463, 2001CrossRefPubMedGoogle Scholar
  10. 10.
    Gill JS, Windebank AJ: Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101: 2442–2450, 1998Google Scholar
  11. 11.
    Cece R, Barajon I, Tredici G: Cisplatin induces apoptosis in SH-SY5Y human neuroblastoma cell line. Anticancer Res 15: 777–782, 1995PubMedGoogle Scholar
  12. 12.
    Miloso M, Mazzotti M, Vass WC, Beguinot L: SHC and GRB-2 are constitutively activated by an epidermal growth factor receptor with a point mutation in the transmembrane domain. J Biol Chem 270: 19557–19562, 1995PubMedGoogle Scholar
  13. 13.
    Casciolo-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A: Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 183: 1957–1964, 1996Google Scholar
  14. 14.
    Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75: 337–349, 1997CrossRefPubMedGoogle Scholar
  15. 15.
    Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG: Cleavage of automodified poly(DNA-ribose) polymerase during apoptosis. Evidence for involvement of caspase 7. J Biol Chem 274: 28379–28384, 1999CrossRefPubMedGoogle Scholar
  16. 16.
    Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P: Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54: 770–777, 1998PubMedGoogle Scholar
  17. 17.
    Reardon JT, Vaisman A, Chaney SG, Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59: 3968–3971, 1999PubMedGoogle Scholar
  18. 18.
    Vaisman A, Chaney SG: The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase β. J Biol Chem 275: 13017–13025, 2000CrossRefPubMedGoogle Scholar
  19. 19.
    Woynarowski JM, Faivre S, Herzig MCS, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE: Oxaliplatininduced damage of cellular DNA. Mol Pharmacol 58: 920–927, 2000PubMedGoogle Scholar
  20. 20.
    Vaisman A, Warren MW, Chaney SG: The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase β on templates with platinum-DNA adducts. J Biol Chem 276: 18999–19005, 2001PubMedGoogle Scholar
  21. 21.
    Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535–1542, 1998CrossRefPubMedGoogle Scholar
  22. 22.
    McKeage MJ, Screnci D, Haddad G, Baguley BC: Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85: 1219–1225, 2001CrossRefPubMedGoogle Scholar
  23. 23.
    Ross RA, Spengler BA, Biedler JL: Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 71: 741–749, 1983PubMedGoogle Scholar
  24. 24.
    Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614–620, 1997CrossRefPubMedGoogle Scholar
  25. 25.
    Allen RT, Cluck MW, Agrawal DK: Mechanisms controlling cellular suicide: role of Bcl-2 and caspases. Cell Mol Life Sci 54: 427–445, 1998PubMedGoogle Scholar
  26. 26.
    Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507–4511, 1995Google Scholar
  27. 27.
    Miyashita T, Masayoshi H, Hanada M, Reed JC: Identifi-cation of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131–3135, 1994PubMedGoogle Scholar
  28. 28.
    Nicolini G, Rigolio R, Scuteri A, Miloso M, Saccomanno D, Cavaletti G, Tredici G: Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int 42: 419–429, 2003CrossRefPubMedGoogle Scholar
  29. 29.
    Del Bello B, Valentini MA, Zunino F, Comporti M, Maellaro E: Cleavage of Bcl-2 in oxidant-and cisplatininduced apoptosis of human melanoma cells. Oncogene 20: 4591–4595, 2001CrossRefPubMedGoogle Scholar
  30. 30.
    Dimmeler S, Breitschopf K, Haendeler J, Zeiher A: Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med 189: 1815–1822, 1999CrossRefPubMedGoogle Scholar
  31. 31.
    Isoe T, Naito M, Hirai R, Tsuruo T: Inhibition of ubiquitin ATP-dependent proteolysis and ubiquitination by cisplatin. Anticancer Res 11: 1905–1909, 1991PubMedGoogle Scholar
  32. 32.
    Peleg-Shulman T, Najajreh Y, Gibson D: Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J Inorg Biochem 91: 306–311, 2002PubMedGoogle Scholar
  33. 33.
    Isoe T, Naito M, Shirai A, Hirai R, Tsuruo T: Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim Biophys Acta 1117: 131–135, 1992PubMedGoogle Scholar
  34. 34.
    Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D: Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791–1798, 1994PubMedGoogle Scholar
  35. 35.
    Kim SS, Chae HS, Bach JH, Lee MW, Kim KY, Lee WB, Jung YM, Bonventre JV, Suh YH: p53 mediates ceramideinduced apoptosis in SKN-SH cells. Oncogene 21: 2020–2028, 2002PubMedGoogle Scholar
  36. 36.
    Malkin D: The role of p53 in human cancer. J Neuro-Oncol 51: 231–243, 2001CrossRefGoogle Scholar
  37. 37.
    Huang C, Ma WY, Maxiner A, Sun Y, Dong Z: p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem 274: 12229–12235, 1999PubMedGoogle Scholar
  38. 38.
    Persons DL, Yazlovitskaya EM, Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778–35785, 2000CrossRefPubMedGoogle Scholar
  39. 39.
    She QB, Chen N, Dong Z: ERKs and p38 kinase phosphorylates p53 protein at serine 15 in response to UV radiation. J Biol Chem 275: 20444–20449, 2000CrossRefPubMedGoogle Scholar
  40. 40.
    Wang X, Martindale JL, Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435–39443, 2000PubMedGoogle Scholar
  41. 41.
    Kim B, Leventhal PS, Saltier AR, Feldman EL: Insulinlike growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation. J Biol Chem 272: 21268–21273, 1997PubMedGoogle Scholar
  42. 42.
    Sanchez-Perez I, Murguia JR, Perona R: Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16: 533–540, 1998PubMedGoogle Scholar
  43. 43.
    Helmuth A, Stefan Q, Julian G, Alexandra L, Florian E, Christian L: The chemotherapeutic oxaliplatin alters voltage-gated Na SUP + channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25–32, 2000Google Scholar
  44. 44.
    Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293–2297, 2001PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Elisabetta Donzelli
    • 1
  • Maria Carfì
    • 1
  • Mariarosaria Miloso
    • 1
  • Alberto Strada
    • 1
  • Stefania Galbiati
    • 1
  • Martine Bayssas
    • 2
  • Genevieve Griffon-Etienne
    • 2
  • Guido Cavaletti
    • 1
    • 3
  • Maria Grazia Petruccioli
    • 4
  • Giovanni Tredici
    • 1
  1. 1.Dipartimento di Neuroscienze e Tecnologie BiomedicheUniversità degli Studi di Milano-BicoccaMonzaItaly
  2. 2.Dipartimento di Neuroscienze e Tecnologie BiomedicheUniversità degli Studi di Milano-BicoccaMonzaItaly
  3. 3.Clinica NeurologicaOspedale San GerardoMonzaItaly
  4. 4.Dipartimento di Anatomia UmanaUniversit`a degli Studi di MilanoMilanoItaly

Personalised recommendations